LifeStance Health Group, Inc.
In the published model solve dated 2026-Q2, anchored at $11.08, LifeStance Health Group, Inc. (LFST) is priced for today's economics sustained for ~19.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• LifeStance runs a national network of outpatient mental-health clinicians employed as W-2 staff, a model built to grow by adding therapists and visits in existing and new centers. • The business is scaling fast, revenue up 21% on an 11% larger clinician base and 18% more visits, but it earns only a thin operating margin today, so the value sits in the growth, not the current profit. • The next reads are clinician hiring and visit volume, the two levers that drive revenue, plus payor reimbursem
Is LFST overvalued? See what's priced in →
218 institutional managers reported holding LFST in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 77%. 41 opened new positions that quarter. Held by FMR (Fidelity), Vanguard Group, BlackRock, among others. On the short side, 8.0M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (3.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
LFST's share count grew 22.2% over the past five years even with $49.11M spent on repurchases. It pays no dividend. Cash returned over the past three years: $49.11M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at LFST over the trailing three years: 2025: 5 buys totaling $498k. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
LFST's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | -5.0% | -23.9% |
| 2023-11-09 | -9.3% | +25.3% |
| 2024-02-29 | +24.6% | -21.8% |
| 2024-05-10 | -1.7% | -22.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
LFST's latest 8-K filings: 2026-07-07 (items 5.02); 2026-06-04 (items 5.07); 2026-05-12 (items 8.01, 9.01); 2026-05-07 (items 2.02, 7.01, 9.01); 2026-03-11 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.